Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Envista Holdings Corporation (NVST) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Instruments & Supplies
$18.27
+0.18 (1.00%)10 Quality Stocks Worth Considering Now
Researching Envista (NVST) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NVST and similar high-potential opportunities.
Based on our analysis of 20 Wall Street analysts, NVST has a neutral consensus with a median price target of $18.25 (ranging from $15.00 to $24.00). The overall analyst rating is Buy (6.6/10). Currently trading at $18.27, the median forecast implies a -0.1% downside. This outlook is supported by 3 Buy, 10 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for NVST.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
May 5, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $18.00 |
Apr 30, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $17.00 |
Apr 29, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $23.00 |
Mar 10, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $21.00 |
Mar 6, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $19.00 |
Mar 6, 2025 | JP Morgan | Rachel Vatnsdal | Neutral | Maintains | $19.00 |
Mar 6, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
Feb 25, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
Feb 6, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $20.00 |
Feb 6, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
Feb 6, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $21.00 |
Feb 3, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $18.00 |
Jan 23, 2025 | Jefferies | Glen Santangelo | Hold | Maintains | $22.00 |
Dec 4, 2024 | Mizuho | Steven Valiquette | Underperform | Initiates | $20.00 |
Oct 31, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
Oct 31, 2024 | Leerink Partners | Michael Cherny | Market Perform | Upgrade | $23.00 |
Oct 31, 2024 | Baird | Jeff Johnson | Neutral | Maintains | $22.00 |
Oct 31, 2024 | Piper Sandler | Jason Bednar | Neutral | Maintains | $17.00 |
Oct 23, 2024 | Stifel | Jonathan Bock | Buy | Maintains | $21.00 |
Oct 8, 2024 | Wells Fargo | Vik Chopra | Equal-Weight | Initiates | $20.00 |
The following stocks are similar to Envista based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Envista Holdings Corporation has a market capitalization of $3.07B with a P/E ratio of 20.8x. The company generates $2.50B in trailing twelve-month revenue with a -44.9% profit margin.
Revenue growth is -1.1% quarter-over-quarter, while maintaining an operating margin of +8.0% and return on equity of -31.3%.
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Develops and sells dental equipment and technology.
Envista Holdings Corporation generates revenue by manufacturing and marketing a diverse range of dental products, including consumables, orthodontic appliances, and imaging equipment. The company serves dental professionals, enhancing their practices with innovative solutions that improve patient care and operational efficiency.
Envista is recognized for its commitment to research and development, continuously introducing advancements that support various sectors of dentistry, such as preventive care and implantology. The company plays a significant role in promoting digital dentistry and setting industry benchmarks for innovation and technology integration.
Healthcare
Medical Instruments & Supplies
12,300
Mr. Paul A. Keel
United States
N/A
Hitachi Digital Services signed a five-year agreement with Envista Holdings to provide IT managed services across its operations in over 60 countries.
Hitachi's five-year agreement with Envista enhances its revenue stream and market presence, potentially boosting investor confidence in both companies' growth and operational efficiency.
Envista's (NVST) overseas revenue trends are influencing Wall Street forecasts and stock prospects, indicating potential shifts in investor sentiment and market performance.
Envista's overseas revenue trends directly influence growth forecasts, affecting stock valuations and investor sentiment, which can lead to stock price volatility.
Envista reported stronger-than-expected earnings and revenue for Q1 2025, surpassing analysts' forecasts.
Envista's strong Q1 2025 performance indicates robust demand and efficient operations, potentially boosting investor confidence and stock price.
Envista Holdings Corporation (NYSE: NVST) will host its Q1 2025 Earnings Conference Call on May 1, 2025, at 5 PM ET, featuring key executives and analysts from various firms.
The earnings call provides insights into Envista's financial health and strategic direction, influencing stock performance and investor sentiment.
Envista Holdings Corporation (NYSE: NVST) reported its quarterly results for the period ending March 28, 2025, on May 1, 2025. Further details on performance were not included.
Quarterly earnings reports can significantly impact stock prices, reflecting a company's performance and future outlook, influencing investor sentiment and trading decisions.
Envista (NVST) has released its quarterly performance data for March 2025, which can be compared to Wall Street estimates and results from the previous year for analysis.
Envista's quarterly performance relative to Wall Street estimates and past results will influence investor sentiment and stock valuation, impacting future trading decisions.
Based on our analysis of 20 Wall Street analysts, Envista Holdings Corporation (NVST) has a median price target of $18.25. The highest price target is $24.00 and the lowest is $15.00.
According to current analyst ratings, NVST has 3 Buy ratings, 10 Hold ratings, and 1 Sell ratings. The stock is currently trading at $18.27. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict NVST stock could reach $18.25 in the next 12 months. This represents a -0.1% decrease from the current price of $18.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
Envista Holdings Corporation generates revenue by manufacturing and marketing a diverse range of dental products, including consumables, orthodontic appliances, and imaging equipment. The company serves dental professionals, enhancing their practices with innovative solutions that improve patient care and operational efficiency.
Price targets from Wall Street analysts for NVST are not currently available. The stock is trading at $18.27.
The lowest price target for NVST is $15.00 from at , which represents a -17.9% decrease from the current price of $18.27.
The overall analyst consensus for NVST is neutral. Out of 20 Wall Street analysts, 3 rate it as Buy, 10 as Hold, and 1 as Sell, with a median price target of $18.25.
Stock price projections, including those for Envista Holdings Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.